Linezolid

Multidrug-resistant bacterial infection is a major clinical challenge in the global anti-infective field at present. Especially for hospital-acquired pneumonia, skin and soft tissue infections caused by Gram-positive bacteria and vancomycin-resistant enterococcal infections, there has been a long-term lack of highly effective and well-tolerated treatment options in clinical practice. Linezolid, as the first oxazolidinone synthetic antibacterial agent applied in clinical practice, selectively binds to the 23S rRNA site of the bacterial 50S ribosomal subunit, blocks the formation of the 70S initiation complex, and inhibits bacterial protein synthesis from the translation initiation stage, with no cross-resistance with other antibacterial agents. Its oral bioavailability is close to 100%, which can meet the sequential treatment demand of intravenous-to-oral switch. It is suitable for adult and pediatric patients with susceptible bacterial infections, providing a critical treatment path in the field of severe anti-infection therapy.

The global linezolid market size exceeded USD 1.8 billion in 2023. With the continuous rise in the detection rate of drug-resistant bacteria and the release of anti-infective demand in primary medical care, the compound annual growth rate is expected to remain at 4.2% by 2028. In terms of the domestic market, this product has been included in the National Medical Insurance Catalog (Class B) and the centralized procurement scope of multiple provinces. The winning bid price has dropped by more than 85% compared with that in the original research period. At present, there are more than 40 approval documents for domestic generic drug preparations, and the market has formed a competitive pattern where the original research drug and leading generic drug enterprises coexist. The localization rate of API has increased to 72%.

The original research enterprise of linezolid is Pfizer, and the original brand name is Zyvox. Its core compound patent expired in 2008 in the United States and in 2009 in China. The main dosage forms approved for the original research drug include tablets (600mg), dry suspension (100mg/5ml) and injections (200mg/100ml, 600mg/300ml). Relevant dosage forms have been included in the China Listed Medicines Catalogue and the FDA Reference Listed Drug Catalogue. Up to now, there are more than 30 linezolid registration records on the CDE API Registration Platform, among which 22 are in status A (approved for use in marketed preparations). More than 30 domestic enterprises have obtained marketing approval for linezolid preparations. (Data as of June 2025, please refer to the official CDE website for the latest information)

CATO provides a full set of impurity reference standards for linezolid API, which can cover the research requirements of the whole process of impurity qualitative and quantitative research and stability investigation. Most products are in stock, and orders placed before 16:00 can be shipped on the same day. All products meet the compliance requirements of multiple regulatory systems such as Chinese Pharmacopoeia and FDA, and can directly support the submission of application documents.